Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813341 | 1.00 | EPHX1 (0.31) | EPHX1GAAPKMTDP1CYP1A2 | |
| SCHEMBL5709 | 1.00 | EPHX1 (0.31) | EPHX1GAAPKMTDP1CYP1A2 | |
| SCHEMBL5118 | 1.00 | EPHX1 (0.31) | EPHX1GAAPKMTDP1CYP1A2 | |
| SCHEMBL5022 | 0.97 | — | — | |
| SCHEMBL5689 | 0.90 | — | — | |
| SCHEMBL349126 | 0.83 | — | — | |
| SCHEMBL28746805 | 0.77 | EPHX1 (0.33) | EPHX1SSTR4 | |
| SCHEMBL879449 | 0.75 | LMNA (0.38) | EPHX1GAAPKMTDP1CYP1A2 | |
| SCHEMBL9897847 | 0.75 | LMNA (0.38) | EPHX1GAAPKMTDP1CYP1A2 | |
| SCHEMBL8502985 | 0.75 | LMNA (0.38) | EPHX1GAAPKMTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | claimed |
| JP-2006526657-A | — | — | 2006-11-24 | — | — | JP | claimed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | claimed |
| EP-1664003-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028454-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | claimed |
| US-20230057670-A1 | NON-AQUEOUS ELECTROLYTE AND ENERGY DEVICE USING SAID NON-AQUEOUS ELECTROLYTE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4123781-A1 | NON-AQUEOUS ELECTROLYTE AND ENERGY DEVICE USING SAID NON-AQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2023-01-25 | — | — | EP | disclosed |
| CN-115315839-A | Nonaqueous electrolyte solution and energy device using same | 三菱化学株式会社 | 2022-11-08 | — | — | CN | disclosed |
| EP-2785695-B1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-0274064-A2 | 2,5,6,7-Tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4361650-A | BACILLUS, STREPTOMYCES OR ACTINOMYCES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-11-30 | — | — | US | disclosed |
| EP-0004466-B1 | DEMETHYL MAYTANSINOIDS AND METHODS FOR PRODUCING THEM | Takeda Chemical Industries, Ltd. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4307016-A | FUNGICIDES, PROTOZOACIDES OR ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | EPHX1 1841/4885GAA 77/4885PKM 1928/4885 |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | EPHX1 791/4885GAA 70/4885PKM 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.